Libni Eapen
Papers
3
Total Citations
607
H-Index
3
About
Dr. Libni Eapen is a leading clinical researcher in head and neck oncology, whose work has fundamentally shaped the debate between surgical and non-surgical treatments for oropharyngeal cancer. Her primary research focus lies in the management of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC), a disease whose incidence has surged dramatically. Dr. Eapen is best known as the principal investigator of the landmark ORATOR trial, a phase II randomized study that directly compared primary radiotherapy to transoral robotic surgery (TORS) with neck dissection for early-stage OPSCC. The trial’s primary results, published in 2019 and cited over 458 times, provided critical, high-level evidence challenging the assumption that TORS is superior to radiotherapy, demonstrating comparable survival but highlighting distinct differences in swallowing-related quality of life. This work has had a profound impact on clinical guidelines and treatment discussions worldwide. By designing and executing this rigorous randomized trial, Dr. Eapen has provided the oncology community with essential data to guide patient counseling and treatment selection in a rapidly evolving field.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3